幹现èç®èæ²»çãšããŠç޹ä»ãããæœè¡ã¯ãå€ãã®å Žåããæ¬äººã®èèªãæ¡åãããã®äžã®çްèãç®èã«æ³šå°ããæ¹æ³ã§ãããã®ãšã䜿ãã®ã¯å¹é€ããŠå¢ããã幹现èã§ã¯ãªããèèªããçŽæ¥åé¢ããçŽ°èæ··åç©ïŒSVFïŒã§ããç®èã«æ³šå°ããåã«èèªæ¡åãšåé¢ã®éçšãå¿ èŠã§ãããããæ¹åãè£ã¥ããæ ¹æ ã¯ãŸã ååã«éãŸã£ãŠããŸããã
åœæ¥ã®æœè¡ã«äœ¿ããã®ã¯äœã
åœéåŠäŒã¯ãåœæ¥åé¢ããSVFãšå¹é€ããŠå¢ããã现èãäºãã«ç°ãªãææãšããŠåºåããŸããåºåã§ã¯ã©ã¡ããã幹现èããšåŒãã§ããå®éã«äœã«å ¥ãããã®ã¯å€ããåŸãŸãã
å¹é€ããŠå¢ããã现èã¯ãéåœåœå ã§ã¯å»è¬åãšããŠæ±ãããŸããåœæ¥åé¢ããSVFã¯å¹é€ãããã©ã®ããã«åé¢ãããã«ãã£ãŠæ³çãªæ±ããç°ãªããŸãã
| åºå | åœæ¥åé¢ããSVF | å¹é€ãã现è |
|---|---|---|
| äœå€å¹é€ | è¡ããªã | å¹é€ããŠæ°ãå¢ãã |
| éåœåœå ã§ã®æ±ã | å颿¹æ³ã«ãã£ãŠç°ãªã | å»è¬å |
| æœè¡ã®æµã | æ¡åããæ¥ã«æ³šå ¥ã§ãã | æ¡åããæ¥ã«ããæ³šå ¥ããªã |
现èã®åç§°ãšæ£äœãããã«è©³ããç¥ãã«ã¯ããèèªå¹¹çްèããšåŒã°ããSVFã¯ãå¹é€ãã幹现èãšã¯ç°ãªããŸãã§ç¢ºèªã§ããŸãã
èèªãæ¡åããŠç®èã«å ¥ãããŸã§
æœè¡ã®æåã®æ®µéã¯ç®è泚å°ã§ã¯ãªããèèªæ¡åã§ããè ¹éšãªã©ããåšå ·ãå ¥ããŠèèªãæ¡åããŸããæ¡åéšäœã®éº»é æ¹æ³ãšæ¡åéãå埩ã«ãããæéã¯ãç®èæ³šå ¥ãšã¯å¥ã«ç¢ºèªããå¿ èŠããããŸãã
æ¡åããèèªããã现èãå«ãéšåãéããŸããé µçŽ ãäœ¿ãæ¹æ³ã¯çްèãã€ãªãæ¢ããŠããç©è³ªãã»ã©ããŠåãé¢ããæ©æ¢°ãäœ¿ãæ¹æ³ã¯çµç¹ãç©ççã«çްããåããŸããè€æ°ã®åœã§ã¯ãé µçŽ åé¢ãçµç¹ã«ããæãå ããæ¹æ³ãšã¿ãªããèŠå¶å¯©æ»ã®å¯Ÿè±¡ãšããŠããŸãã
åé¢ãçµãããšãéãã现èãç®èã«åããŠæ³šå°ããŸããã©ã®éšäœãšç®èå±€ã«ã©ãã ãå ¥ãããã¯ãå»çæ©é¢ã®æœè¡èšç»ã«ãã£ãŠæ±ºãŸããŸãã
| 段é | å®éã«è¡ãããš | 確èªããç¹ |
|---|---|---|
| èèªæ¡å | è ¹éšãªã©ããèèªãåãåºã | 麻é ãæ¡åéšäœãšéãå埩 |
| åé¢ | é µçŽ ãŸãã¯æ©æ¢°ã§çްèãå«ãéšåãéãã | å颿¹æ³ |
| ç®èæ³šå ¥ | 決ããç®èå±€ã«åããŠæ³šå° | æ³šå ¥éšäœãšèšç» |
å šäœã®é²è¡æ§æãšãã»ãã®èªå®¶ç±æ¥æœè¡ãšã®éãã¯ãSVFæœè¡ã®è©³çްãšNovaStemã»SVFã»PRFæ¯èŒã«ãŸãšããŠããŸãã
ç®èã§ç¢ºèªãããå€å
äºã€ã®ç ç©¶ãåãããŠã¿ãŸãããããããæžã£ããšèšããçµæã¯åºãŠããããäºã€ã®ç ç©¶ã®çµæãäºãã«å€§ããç°ãªããŸãããè²çŽ ã®å€åããç ç©¶ããšã«æ¹åãç°ãªããŸããã
ããç ç©¶ã§ã¯åŒŸåãšç®èå åŽã®å¯åºŠã»åããå¢ããŸããããæ©åšã§æž¬ã£ããããšã»ãããç·ã®å€èŠã¯ãæœè¡åãšåçšåºŠã«ãšã©ãŸããŸãããç®èå€åŽå±€ã®å¯åºŠããã®ãŸãŸã§ããã
ã¬ãŒã¶ãŒããè¡æ¶²ããè¡å°æ¿ã®å€ãéšåãéããPRPã䜵çšããå ŽåãSVFã ãã䜿ã£ããšãããè¯ãçµæãå ±åãããŸããããã®èšé²ã¯äºã€ã®æœè¡ãäžç·ã«è¡ã£ãçµæã§ãããããSVFäžçš®ã®å€åãšããŠèªãã«ã¯å¥ã®ç ç©¶ãå¿ èŠã§ãã
â» ç ç©¶ããšã«æœè¡æ¹æ³ãšèг坿éãè©äŸ¡ããŒã«ãç°ãªããäžéšã®çµæã¯æ¯èŒå¯Ÿè±¡ãªãã«äžã€ã®éå£ã ãã芳å¯ããç ç©¶ããåºãŠããŸãã
ãããŸã§ã«å ±åãããå¯åå¿
èšåºè³æã§äž»ã«å ±åãããæå®³äºè±¡ã¯ãäžæçãªçã¿ãè «ããæ³šå°éšäœã®ççã§ãããè¡ç®¡éå¡ãçµç¹ã硬ããªãçŸè±¡ãææãè «çã®ãããªé倧ãªåé¡ã¯ãèšåºçäŸãéããè³æã§å ±åä»¶æ°0ãšéèšãããŸããããã ãè³æãå°ãªãèŠ³å¯æéãçããããçŸåšç¢ºèªãããŠããç¯å²ã¯çæã®å®å šæ§ã§ãã
èèªç§»æ€ã«SVFãå ããç ç©¶ãéããè³æã§ã¯ãæé·4幎ãŸã§ææãå¢èãèèªå£æ»ãè «çåçºã®é »åºŠãæœè¡åãšåçšåºŠã«ç¶æãããŸãããç®èã«SVFã ããæ³šå°ããæœè¡ãšã¯æ¡ä»¶ãç°ãªãçµæã§ãã
æ³šå ¥çµè·¯ãå€ãããšããªã¹ã¯ãå€ãããŸããèªå®¶èèªç±æ¥çްèãçŒå ã«æ³šå°ããã3åã«ãäž¡çŒã®é床ã®èŠååªå€±ãçããäºäŸãå ±åãããŸããããæ¬äººã®çµç¹ã§ãããšããäºå®ããããã©ãã«ã©ã®ãããªæ¹æ³ã§å ¥ããããŸã§ç¢ºèªããå¿ èŠãããçç±ã§ãã
æ³åŸãšå¶åºŠãçãåã
ãã®æ³åŸãããå 端åçå»çã¯ãéçã»åžå°ã»é£æ²»çŸæ£ã®æ²»çã®ããã®å¶åºŠã§ããã察象ãšãªãæ£è ããã®ç¯å²ã«éãããŸããç®èçŸå®¹ã¯ããããå€ããŠããããããå 端åçå»çã®æ¿èªããšãã衚çŸãèãããšãã¯ãã©ã®æç¶ããšã©ã®çŸæ£ãæãã®ããåãè¿ãå¿ èŠããããŸãã
åœå®¶è©äŸ¡ãçµãŠåèŒãããèªå®¶èèªç±æ¥SVFæè¡ã¯ãç¹å®ã®çŸæ£äºã€ã ãã§ãããæ¡ä»¶ãå³ããå®ããããŠããŸããç®èã»çŸå®¹ç®çã§åèŒãããæè¡ã¯0ä»¶ã§ãããã®åºåã¯æœè¡ã®é©æ³æ§ãå€å®ããåºæºã§ã¯ãªããåœå®¶è©äŸ¡ã®äžèЧã«ã©ã®æè¡ãèŒã£ãŠãããã瀺ããã®ã§ãã
æœè¡ã®åã«ã¯ãåç§°ãããæ¡åã»åé¢ã»æ³šå ¥ã®å®éã®éçšã確èªããæ¹ãæ£ç¢ºã§ãã
- â¡ èèªãé µçŽ ã§åé¢ããŸãããæ©æ¢°ã§åé¢ããŸããïŒ
- â¡ åœæ¥æ³šå°ããææã¯ãå¹é€ããŠããªãSVFã§ããïŒ
- â¡ ãå 端åçå»çã®æ¿èªããã©ã®æç¶ããæããèããŸãããïŒ
- â¡ åèŒãæ ¹æ ãšããŠæç€ºãããå ŽåãåèŒãããçŸæ£ãšé©çšæ¡ä»¶ã確èªããŸãããïŒ
- â¡ èèªæ¡åãšç®èæ³šå ¥ã®ãªã¹ã¯ãæ¡åéšäœã®å埩æéãããããèããŸãããïŒ
- â¡ æçšäžã®è¬ãåŠåš ã»æä¹³ãæŽ»åæ§ææãèªå·±å ç«çŸæ£ãæœè¡åã«äŒããŸãããïŒ
èŠç©æžã¯ãæ¡åã»åé¢ã»æ³šå ¥ã»äœµçšæœè¡ã®ãã¡ã©ããŸã§ãå«ãã éé¡ããåããŠç¢ºèªããŠãã ãããæœèšãšææç®¡çãææ¥å¯Ÿå¿ãªã©ãå»çæ©é¢ãéžã¶äžè¬çãªåºæºã¯å¹¹çްèã®å®å šãªå»é¢ã®éžã³æ¹ã§ã芧ããã ããŸãã
ãããã質å
Q1. SVFæœè¡ã¯çã¿ãŸããïŒ
èèªãæ¡åãããšãã«åšå ·ãå ¥ããåé¢ãã现èãç®èã«åã³æ³šå°ããŸããè³æã§ã¯äžæçãªçã¿ãšè «ããäž»ã«å ±åãããŸãããæ¡åéšäœã®éº»é æ¹æ³ãšç®èæ³šå ¥ã®æ¹æ³ãåããŠç¢ºèªããŠãã ããã
Q2. èªå®¶çµç¹ãªãå®å šã§ããïŒ
èªå®¶çµç¹ãšã¯ãææããæ¬äººããåŸããšããæå³ã§ããèèªæ¡åãšç®èæ³šå ¥ã®ãªã¹ã¯ã¯ããããæ®ããããäºã€ã®éçšãå¥ã«èª¬æããŠãããå¿ èŠããããŸãã
Q3. ã¬ãŒã¶ãŒãPRPãšäžç·ã«åããŠãããã§ããïŒ
ç ç©¶ã«ã¯ãã¬ãŒã¶ãŒãPRPã䜵çšããèšé²ããããŸãã䜵çšã®å¯åŠãšå®æœã®é åºã¯ãæœè¡åã«æ±ºããŠãããŠãã ãããäžç·ã«åãããšãã®çµæã¯ãäºã€ã®æœè¡ãåãããçµæãšããŠèªãæ¹ãæ£ç¢ºã§ãã
Q4. æœè¡åã«ã©ã®ãããªå¥åº·ç¶æ ãäŒããå¿ èŠããããŸããïŒ
æçšäžã®è¬ãããå ŽåãåŠåš ã»æä¹³äžã®å ŽåãæŽ»åæ§ææãèªå·±å ç«çŸæ£ãããå Žåã¯ãæœè¡åã«äŒããå¿ èŠããããŸããè¡æ¶²ãããããã«ããè¬ãå ç«æå¶å€ãæçšããŠããå Žåã¯ãããããŠäŒããŠãã ããã
Q5. SVFãšPRPã»PRFã¯åãæœè¡ã§ããïŒ
SVFã¯èèªããåŸãŠãPRPãšå€è¡å°æ¿ãã£ããªã³ïŒPRFïŒã¯è¡æ¶²ããæºåããŸããæ¡åããçµç¹ãç°ãªããããå颿¹æ³ãšæºåã®é åºãç°ãªããŸãã詳ããéãã¯PRFãšSVFã®éãã§ç¢ºèªã§ããŸãã
çµæã»æç¶ã»é©åã®å¯åŠã¯ããäžäººãã²ãšãã®èç¶æ ã»å¹Žéœ¢ã»çæŽ»ç¿æ £ã«ãã£ãŠå·®ããããåãçµæããçŽæããããšã¯ã§ããŸããã
æœè¡ã«ã¯äžæçãªèµ€ã¿ã»ããã¿ãªã©ã®å¯åå¿ãçããå¯èœæ§ããããçŠå¿äºé ãããå ŽåããããŸãã®ã§ãäºåã«ãŠã³ã»ãªã³ã°ã§ã確èªãã ããã
æ¬èšäºã¯äžè¬çãªæ å ±ã®ãæ¡å ã§ãããåå¥ã®èšºçã«ä»£ãããã®ã§ã¯ãããŸããããèªèº«ã®ç¶æ ã«åããã蚺æã»æœè¡ã¯ã«ãŠã³ã»ãªã³ã°ã§ã確èªãã ããã
æ ¹æ è³æ
- Bourin Pã»ãïŒ2013ïŒãCytotherapy: Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)ïŒPMID 23570660ïŒ
- Dominici Mã»ãïŒ2006ïŒãCytotherapy: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementïŒPMID 16923606ïŒ
- Trivisonno Aã»ãïŒ2019ïŒãStem Cells Transl Med: Intraoperative Strategies for Minimal Manipulation of Autologous Adipose Tissue for Cell- and Tissue-Based Therapies: Concise ReviewïŒPMID 31599497ïŒ
- A Systematic Review of Adipose-Derived Cell Therapies on Skin Quality (2025, PMID 40852442)
- Amirkhani MAã»ãïŒ2016ïŒãBioimpacts: Rejuvenation of facial skin and improvement in the dermal architecture by transplantation of autologous stromal vascular fraction: a clinical studyïŒPMID 27853678ïŒ
- Hakami AHã»ãïŒ2025ïŒãCureus: Adipose-Derived Stem Cell, Stromal Vascular Fraction, and Regenerative Cell Enrichment in Fat Grafting: A Systematic Review of Safety and Functional OutcomesïŒPMID 41555993ïŒ
- Safety profile of autologous adipose-derived stromal vascular fraction in clinical use (2026, PMID 41618435)
- èªå·±èèªç±æ¥çްèã®çŒå æ³šå ¥åŸã«é床ã®èŠååªå€±ãããããçäŸ, New England Journal of Medicine (2017, PMID 28296617)
- åœå®¶æ³ä»€æ å ±ã»ã³ã¿ãŒïŒå 端åçå»çåã³å 端ãã€ãªå»è¬åå®å šã»æ¯æŽã«é¢ããæ³åŸïŒå 端åçãã€ãªæ³ïŒããã³åæœè¡ä»€
- éåœä¿å¥çŠç¥éšïŒæ°å»çæè¡ã®å®å šæ§ã»æå¹æ§è©äŸ¡çµæã«é¢ããå瀺ïŒ2026幎8æ10æ¥æœè¡ïŒ
ããããŠèªã
çŸåšã®ç¶æ ã«åãæœè¡çžè«
çŸåšã®å¥åº·ç¶æ ãšéå»ã®æœè¡æŽã確èªããããã§ãæ€èšå¯èœãªéžæè¢ãšéçããæ¡å ããŸãã



